Angiotensin (1-7) and other angiotensin peptides

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3060-3064

  Ohishi, Mitsuru ^a   Yamamoto, Koichi ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE2; Angiotensin (1 7); Angiotensin IV; IRAP; Mas receptor

Indexed keywords

ANGIOTENSIN (1-9); ANGIOTENSIN (2-8); ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II [3-8]; ANGIOTENSIN[1-7]; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; GENE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; MAS GENE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; GLUCOSE; HUMANS; KIDNEY DISEASES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84878631527     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170013     Document Type: Article

References (56)

1. Nassis L, Frauman AG, Ohishi M, et al. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol 2001; 195: 571-9.
2. Dinh DT, Frauman AG, Somers GR, et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 2002; 196: 213-9.
3. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15: 1295-302.
4. Ohishi M, Ueda M, Rakugi H, et al. Upregulation of angiotensinconverting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 1997; 96: 3328-37.
5. Ohishi M, Ueda M, Rakugi H, et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens 1999; 17: 547-53.
6. Okamura A, Rakugi H, Ohishi M, et al. Upregulation of reninangiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-45.
7. Yanagitani Y, Rakugi H, Okamura A, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999; 33: 335-9.
8. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114: 2850-70.
9. Horiuchi M, Mogi M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol 2011; 163: 1122-30.
10. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
11. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
12. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
13. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.
14. Jackson TR, Blair LA, Marshall J, Goedert M, Hanley MR. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437-40.
15. Von Bohlen und Halbach O, Walther T, Bader M, Albrecht D. Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J Neurophysiol 2000; 83: 2012-21.
16. Agata J, Ura N, Yoshida H, et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensinconverting enzyme. Hypertens Res 2006; 29: 865-74.
17. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-7.
18. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens 2012; 2012: 307315.
19. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006; 47: 718-26.
20. Shiota A, Yamamoto K, Ohishi M, et al. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens Res 2010; 33: 298-307.
21. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888-97.
22. Gupte M, Thatcher SE, Boustany-Kari CM, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 2012; 32: 1392-9.
23. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11: 875-9.
24. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-6.
25. Zheng H, Liu X, Patel KP. Angiotensin-converting enzyme 2 overexpression improves central nitric oxide-mediated sympathetic outflow in chronic heart failure. Am J Physiol Heart Circ Physiol 2011; 301: H2402-12.
26. Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806-13.
27. Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 2003; 108: 1707-12.
28. Chiodetti L, Choi S, Barber DL, Schwartz RH. Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol 2006; 176: 2279-91.
29. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6.
30. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-9.
31. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-8.
32. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005; 45: 138-41.
33. Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-50.
34. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-8.
35. Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 2008; 51: 574-80.
36. Hayashi N, Yamamoto K, Ohishi M, et al. The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res 2010; 33: 1182-5.
37. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-7.
38. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43: 1120-5.
39. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-75.
40. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51: 613-23.
41. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-6.
42. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72: 614-23.
43. Wong DW, Oudit GY, Reich H, et al. Loss of angiotensinconverting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007; 171: 438-51.
44. Tikellis C, Bialkowski K, Pete J, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-25.
45. Abuissa H, Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6.
46. Santos SH, Fernandes LR, Mario EG, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-7.
47. Gupte M, Boustany-Kari CM, Bharadwaj K, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008; 295: R781-8.
48. Fernandes T, Hashimoto NY, Oliveira EM. Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats. Braz J Med Biol Res 2010; 43: 837-42.
49. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
50. Takeda M, Yamamoto K, Takemura Y, et al. Loss of Angiotensinconverting enzyme 2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes in press.
51. Zhuo J, Moeller I, Jenkins T, et al. Mapping tissue angiotensinconverting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16: 2027-37.
52. Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin IV (AT(4) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-6.
53. Pham V, Albiston AL, Downes CE, et al. Insulin-regulated aminopeptidase deficiency provides protection against ischemic stroke in mice. J Neurotrauma 2012; 29: 1243-8.
54. Loyens E, Schallier A, Chai SY, et al. Deletion of insulin-regulated aminopeptidase in mice decreases susceptibility to pentylenetetrazol-induced generalized seizures. Seizure 2011; 20: 602-5.
55. Wong YC, Sim MK, Lee KO. Des-aspartate-angiotensin-I and angiotensin IV improve glucose tolerance and insulin signalling in diet-induced hyperglycaemic mice. Biochem Pharmacol 2011; 82: 1198-208.
56. Fernando RN, Albiston AL, Chai SY. The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus-potential role in modulation of glucose uptake in neurones? Eur J Neurosci 2008; 28: 588-98.